ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1398	National Cancer Institute	Html	en	Skin Cancer Prevention (PDQ®)–Patient Version	Expert-reviewed information summary about factors that may influence the risk of developing skin cancer and about research aimed at the prevention of this disease.	skin cancer risk 0.467928 skin cancer 0.941497 cancer treatment 0.38312 cancer prevention trials 0.475588 skin cancer prevention 0.535336 prevention clinical trials 0.429013 protective factors 0.444137 following PDQ summaries 0.42969 PDQ cancer information 0.571591 recurrent nonmelanoma skin 0.412014 squamous cells 0.377891 Clinical Trials section 0.386332 clinical trials 0.585589 cancer information summary 0.499343 melanoma skin cancer 0.517983 breast cancer prevention 0.410906 cancer patients 0.382129 latest published information 0.38194 cancer risk factor 0.448186 NCI’s PDQ 0.391159 UV radiation 0.512203 NCI PDQ cancer 0.462016 basal cell carcinoma 0.591274 new cases 0.414085	PDQ Screening 0.380155 cancer risk factors 0.449906 Cancer prevention 0.618596 cancer protective factor 0.429755 new skin cancers 0.427053 new actinic keratoses 0.38071 Cancer Information Service 0.419558 slightly lower rates 0.381858 nonmelanoma skin cancers 0.666071 Prevention Editorial Board 0.428923 treatment clinical trials 0.387193 National Cancer Institute 0.507676 PDQ documents 0.381747 D. The skin 0.379577 new treatment 0.382048 Cancer Care page 0.40764 PDQ database 0.385226 PDQ summary 0.416284 melanoma prevention trials 0.402284 cancer clinical trials 0.430331 risk factors 0.646155 cancer information summaries 0.426847 nonmelanoma skin cancer 0.802884 comprehensive cancer information 0.42608	CLICK HERE
1472	National Cancer Institute	Html	en	Endometrial Cancer Treatment (PDQ®)–Health Professional Version	Endometrial cancer is usually diagnosed at an early stage and can be treated with surgery. Learn about the symptoms, diagnosis, prognosis, staging, and treatment for early- and advanced-stage endometrial cancer in this expert-reviewed summary.	Obstet Gynecol 0.477047 papillary serous carcinoma 0.485706 endometrial cancer staging 0.480093 uterine cancer 0.371407 positive peritoneal cytology 0.407977 endometrial carcinoma 0.678904 normal endometrial 0.464798 endometrial cancer stage 0.512175 Int J Radiat 0.414383 Radiat Oncol Biol 0.512336 surgical staging 0.377398 oncology group study 0.48351 prognostic significance 0.39336 Natl Cancer Inst 0.399994 cell endometrial cancer 0.498772 Gynecologic Oncology Group 0.519757 endometrial hyperplasia 0.463477 Gynecol Oncol 0.817345 radiation therapy 0.404405 endometrial cancer 0.939144 early-stage endometrial cancer 0.512325 peritoneal cytology 0.432244 stage-1 endometrial carcinoma 0.468917 endometrial lining 0.46346 et al. 0.506597	clear cell endometrial 0.473365 progesterone receptor content 0.393655 stage endometrial cancer 0.540703 stage uterine papillary 0.382976 serous endometrial cancer 0.492942 type endometrial cancer 0.479957 endometrial tissue 0.462216 papillary serous cancer 0.3874 endometrial cancer patients 0.547475 early stage endometrial 0.515429 stage IIB patients 0.37429 risk endometrial adenocarcinoma 0.459895 Endometrial Cancer Study 0.48075 surgical-pathological risk factors 0.372575 endometrial canal 0.462243 comprehensive surgical staging 0.375341 Abstract 0.581453 progesterone receptor levels 0.46561 Clin Oncol 0.418943 surgical stage 0.412306 Oncol Biol Phys 0.518638 uterine papillary 0.386955 clinical stage 0.37895 vaginal brachytherapy 0.371898	CLICK HERE
1483	National Cancer Institute	Html	en	Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of Kaposi sarcoma.	classic ks 0.718451 azathioprine developed KS 0.600594 skin surface area 0.47235 systemic lesions 0.493932 indolent course 0.470841 mucocutaneous lesions 0.512302 renal transplant 0.501016 visceral lesions 0.497461 KS involvement 0.562512 KS incidence 0.560945 KS lesions 0.599331 Pleuropulmonary KS 0.5556 HIV disease patients 0.521452 relatively common neoplasm 0.471596 widespread mucocutaneous lesions 0.507995 patients 0.634408 renal transplant patient 0.470087 drug-resistant HIV strains 0.474114 immunosuppressive therapy 0.478552 lymph nodes 0.596884 renal transplant patients 0.496667 gastrointestinal tract 0.58589 rare disease 0.483334 classic KS tumor 0.622697 detectable visceral organ 0.475328	iatrogenically immunosuppressed patients 0.494142 numerous lesions 0.474766 opportunistic infections 0.508602 HIV disease 0.544402 gastrointestinal tract disease 0.488821 KS treatment 0.552981 innumerable skin lesions 0.514662 standard tumor assessment 0.472883 visceral organ involvement 0.584749 disease 0.576658 African KS 0.57237 AIDS patients 0.479351 epidemic KS die 0.595228 classical KS 0.550709 rapidly progressive tumor 0.472892 KS 0.931586 Classic KS tumors 0.625414 generalized KS 0.572002 skin disease 0.482408 epidemic KS 0.750866 skin lesions 0.586652 additional lesions 0.488289 nodular skin lesions 0.53343 biopsy-proven KS 0.558149	CLICK HERE
1695	National Cancer Institute	Html	en	High-Dose Vitamin C (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of high-dose vitamin C as a treatment for people with cancer.	ascorbic acid cause 0.642882 prostate cancer cell 0.630423 /IV ovarian cancer 0.57305 oral ascorbic acid 0.649173 vitamin C therapy 0.612109 vitamin C. 0.610223 cancer information summary 0.591614 weekly ascorbate infusions 0.607343 multiple myeloma patients 0.578578 ovarian cancer 0.574477 cancer patients 0.68661 vitamin 0.72459 high-dose vitamin 0.665873 oral vitamin 0.706163 significant adverse events 0.605455 high-dose IV ascorbate 0.593412 colon cancer cells 0.587994 ascorbic acid treatment 0.848969 metastatic colorectal cancer 0.572155 vitamin C supplements 0.616683 ascorbic acid 0.99701 study 0.585466 current clinical trials 0.571291 case series 0.594589 tumor volume 0.583085	pancreatic cancer patients 0.683645 dehydroascorbic acid 0.640204 terminal cancer patients 0.626123 cancer cells 0.588032 bortezomib growth inhibition 0.576885 high-dose ascorbic acid 0.717915 studies 0.596394 pharmacological ascorbate 0.581055 breast cancer cells. 0.579255 decrease cell proliferation 0.57116 ascorbic acid synthesis 0.660705 cancer cell lines. 0.642672 L-ascorbic acid 0.574809 intracellular ascorbic acid 0.648545 high-dose IV vitamin 0.658734 healthy volunteers 0.583492 inhibitory effect 0.590166 cancer cell death 0.591483 oxidized form 0.602818 cancer cell xenografts 0.58194 ascorbic acid. 0.583971 ascorbate 0.663468 tumor inhibitory effect 0.580256 cancer 0.692622	CLICK HERE
1839	National Cancer Institute	Html	es	Tratamiento de los tumores del sistema nervioso central en adultos (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de los tumores del sistema nervioso central en adultos.	carmustina versus 0.548633 malignant glioma 0.86408 WB Saunders Co 0.553184 American Cancer Society 0.574098 sumario tratamiento 0.554962 cuáles pacientes 0.551482 primary gliomas located 0.577278 idh1 mutation 0.550619 IDH2 mutations 0.547874 Radiation Therapy Oncology 0.556783 Radiat Oncol Biol 0.675252 central nervous system 0.6889 patients with 0.664355 Medical Research Council 0.587686 Brain Tumor Research 0.559245 Acta Neuropathol 0.563339 cerebral low-grade glioma 0.542243 diagnosed malignant glioma 0.650146 who classification 0.562467 Neuroimaging Clin 0.54527 chemotherapy with 0.549687 patients with glioblastoma 0.549124 tumor group study 0.541376 Organización Mundial 0.549658 Research Council Brain 0.538383	malignant glioma after 0.544669 Cancer Treatment 0.573642 Ohgaki H 0.558609 mortalidad posoperatoria 0.540841 patients with idh1 0.548495 Bent MJ 0.548927 Therapy Oncology Group 0.603297 radioterapia posoperatoria 0.576011 BRAF V600E 0.543097 low-grade glioma 0.559845 primary malignant glioma 0.547729 conventional radiotherapy with 0.572491 National Cancer Institute 0.578026 radiotherapy with 0.578973 newly diagnosed malignant 0.564043 características histológicas 0.717766 Radiation-induced malignant gliomas 0.578762 Clin Oncol 0.624379 sistema nervioso central 0.979769 brain tumor 0.782394 Oncol Biol Phys 0.679866 adult brain tumors 0.545694 Cancer Institute 0.592793 brain tumour 0.610029	CLICK HERE
1841	National Cancer Institute	Html	es	Tratamiento del cáncer de intestino delgado (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de intestino delgado.	Serour F 0.235745 Lippincott Williams 0.238115 Compton CC 0.588526 M)a aReproducción 0.23829 accessed october 0.241973 Definiciones TNM 0.236983 American Cancer Society 0.407525 7th ed 0.585523 Zeh HJ III 0.264951 Zureikat AH 0.235019 Dona G 0.235003 Small bowel tumors 0.287594 Instituto Nacional 0.346133 DeVita VT Jr 0.263261 Malignant tumors 0.234868 Chen CC 0.239394 Eto T 0.235436 Rosenberg SA 0.234255 tumores carcinoides 0.932641 Tsunoda T 0.234397 Lawrence TS 0.234618 malignant neoplasms 0.237309 tumores carcinoides gastrointestinales 0.457635 estadio ii 0.290896 Cancer Facts 0.258856	Ahsan H 0.236233 Birkenfeld S 0.235158 malignant small bowel 0.287742 Am Surg 0.243892 Cancer Staging Manual 0.891975 National Cancer Institute 0.259977 small bowel 0.440838 rara vez 0.23641 Surg Oncol 0.338089 PDQ Tratamiento 0.993362 New York 0.545893 Primary neoplasms 0.238508 9th ed 0.239679 Physician Data Query 0.250873 Hochwald SN 0.233655 Byrd DR 0.571234 Matsuo S 0.234278 Heller MT 0.2353 Primary duodenal 0.236001 Am Coll Surg 0.2682 Tis Carcinoma 0.238384 T)a aReproducción 0.237792 AJCC Cancer Staging 0.895181 Edge SB 0.590374	CLICK HERE
2057	National Cancer Institute	Html	es	Cáncer de hueso	Hoja informativa acerca del diagnóstico y tratamiento de los cánceres que se presentan en los huesos.	Lippincott Williams 0.528921 Pediatric Oncology 0.425852 DeVita VT 0.423199 Grandes avances 0.423263 Fischbach FT 0.422317 tejido óseo 0.925192 rayos x 0.477476 American Cancer Society 0.521554 página web guía 0.432205 7th ed 0.466045 altas dosis 0.425962 enfermedades infantiles congénitas 0.446544 Diagnostic Tests 0.424605 fosfatasa alcalina 0.483649 distintos tipos 0.471502 médico pregunta 0.42954 Pizzo P 0.423691 Estados Unidos 0.422015 survival among children 0.439442 Boice JD 0.42308 Rosenberg SA 0.420738 Fraumeni JF 0.42331 tumor óseo 0.736727 Schottenfeld D 0.42165	States SEER Program 0.439663 importante opción 0.422974 mejores formas 0.420225 pequeña cantidad 0.471903 editors.  cancer 0.434055 gammagrafía ósea 0.428461 O'Sullivan B 0.421908 Malawer MM 0.422909 Curtis RE 0.421362 probables beneficios 0.422945 National Cancer Institute 0.447941 4th ed 0.425929 Ries LAG 0.424185 Ewing Sarcoma Family 0.452617 Hellman S 0.421499 Dunning MB 0.422439 Retrieved March 0.423884 emission tomography 0.426368 enzima llamada 0.426279 cabo estudios 0.429851 Helman LJ 0.424392 Gurney JG 0.42319 Poplack DG 0.422887 Miller RW 0.421236	CLICK HERE
4390	National Cancer Institute	Html	en	Tobacco	null	safe level 0.460816 death 0.358553 Monday 0.354828 throat 0.333618 cause 0.328958 stomach 0.336801 LiveHelp pop-up 0.465489 kidney 0.330373 acute myeloid leukemia 0.608856 Friday 0.35571 pancreas 0.384789 smoking 0.405609 harms 0.335823 tobacco 0.963237 damage DNA 0.469968 cessation counselors 0.452946 secondhand smoke 0.632466 chemicals 0.330701 cervix 0.34121 tobacco product 0.60509 a.m. 0.346985 types 0.328829	confidential information 0.439568 liver 0.32937 People 0.42541 cancer diagnosis 0.44607 p.m. 0.346876 environmental tobacco smoke 0.826608 substantial gains 0.462279 ET 0.353868 life expectancy 0.459232 lung 0.329921 tobacco products 0.728115 smokeless tobacco 0.623945 snuff 0.336877 mouth 0.374264 NCI quitline 0.460061 bladder 0.333336 colon 0.333223 cancers 0.332967 online 0.346425 cancer 0.481797 risk 0.357987 rectum 0.343994	CLICK HERE
15643	National Cancer Institute	Html	en	Grants Policies and Process	NIH prior approval is required for the transfer of a grant. Learn more about transferring a cancer research grant from one entity to another.	National Cancer Institute 0.966549		CLICK HERE
16709	National Cancer Institute	Html	es	ALCHEMIST (Estudios sobre la Secuenciación e Identificación de Marcadores para el Mejoramiento de la Terapia Adjuvante para el Cáncer de Pulmón): Preguntas y respuestas	ALCHEMIST comprende tres estudios clínicos integrados de medicina de precisión diseñados para identificar a personas con cáncer de pulmón en estadio inicial cuyos tumores tienen ciertos cambios genéticos poco comunes. También buscan evaluar si los tratamientos con medicamentos que combaten esos cambios moleculares pueden mejorar la supervivencia	Geoffrey Oxnard 0.313105 estudios clínicos alchemist 0.419541 genes egfr 0.537115 tumor carcinoide 0.318935 gen alk 0.998441 estudio alchemist 0.428836 cáncer nsclc 0.336759 Clinical Trials 0.385899 Washington University 0.311286 estudios alchemist hombres 0.406835 Dana-Farber Cancer Institute 0.323728 estadio ib 0.321816 largo plazo 0.311737 Cáncer ECOG-ACRIN 0.357818 Clinical Laboratory Improvement 0.323435 Cancer Enrichment Marker 0.325429 Cancer Genome Analysis 0.324094 Pasi A 0.313281 compañías farmacéuticas socias 0.322405 National Human Genome 0.322496 Instituto Nacional 0.327493	estadio iiia 0.321214 David E 0.311651 Terapia Adjuvante 0.312862 NCI Community Oncology 0.329248 Genoma Humano 0.311302 Ramaswamy Govindan 0.314989 gen egfr 0.724341 alchemist correspondientes 0.435182 Estados Unidos 0.373254 Texas Southwestern Medical 0.321883 cabo estudios 0.336005 principales objetivos 0.311051 Vysis ALK break-apart 0.345879 compañía response genetics 0.320675 estudios alchemist 0.840169 Astellas Pharma US 0.321115 Cancer Genomics 0.314435 Oncología NRG 0.312826 radioterapia posoperatorias 0.315764 Sequencing Trials 0.317534 Institutos Nacionales 0.331134	CLICK HERE